FDA and EMA Seek Candidates for GMP Inspection Pilot - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA and EMA Seek Candidates for GMP Inspection Pilot


ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Food and Drug Administration and European Medicines Agency (EMA) are looking for drug-manufacturing companies to participate in their joint good manufacturing practice (GMP) inspection pilot program.

A new EMA release states that companies that have submitted two separate but equivalent new drug application applications to EMA and FDA are eligible to participate in the pilot. Such companies will be inspected jointly by the regulatory agencies. In addition, if a company is expecting a routine surveillance or re-inspection by both agencies, that company can also participate in the pilot by hosting a single joint inspection.

“The overall objective is to see whether greater international collaboration can help to distribute inspection capacity allowing more manufacturing sites to be monitored and reducing unnecessary duplication,” says the EMA release.

Over the past couple of years, the agencies have conducted similar pilot programs. FDA, EMA and the Australian drug regulatory agency conducted an 18-month joint pilot inspection program focused on active pharmaceutical ingredient manufacture in countries outside of the three regions. This pilot officially began in November 2008. FDA and EMA ran a joint inspection pilot program of companies manufacturing drugs in both regions beginning in the spring of 2009 in order to better share information. The two agencies also ran an 18-month joint good clinical practices initiative starting in September 2009 to increase collaborative efforts to inspect clinical trial sites and studies.

The new GMP pilot program that is getting underway is meant to build on these experiences. Companies interested in the pilot should contact their respective agency at CDERInternationalGMP@fda.hhs.gov or gmp@ema.europa.eu.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here